CIK 0001818794 · Large accelerated filer
Dyne Therapeutics, Inc.
Sign in to watch- Ticker
- DYN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364883909
- Phone
- (781) 786-8230
- Business address
- 1560 TRAPELO ROAD, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $40,000
- in 1 filing
- Open-market sales, last 90 days
- $247,777
- in 3 filings, $248K under 10b5-1 plans
Net −$207,777. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-11 | McNeill Jonathan Chief Business Officer | Sale 10b5-1 | −17,825 | $25.48 | $454K | 141,184 |
| 2024-03-11 | McNeill Jonathan Chief Business Officer | Sale 10b5-1 | −1,776 | $25.71 | $46K | 139,408 |
| 2024-03-11 | McNeill Jonathan Chief Business Officer | Option exercise · Stock option (right to buy) 10b5-1 | −17,825 | 0 | ||
| 2024-03-11 | Farwell Wildon Chief Medical Officer | Sale 10b5-1 | −1,585 | $25.70 | $41K | 151,590 |
| 2024-03-11 | Scalzo Richard William SVP, Head of Finance & Admin. | Sale 10b5-1 | −1,082 | $25.70 | $28K | 120,873 |
| 2024-03-11 | Scalzo Richard William SVP, Head of Finance & Admin. | Sale 10b5-1 | −1,590 | $24.99 | $40K | 119,283 |
| 2024-03-11 | Brumm Joshua T CEO & President | Option exercise 10b5-1 | +50,000 | $5.54 | $277K | 604,385 |
| 2024-03-11 | Brumm Joshua T CEO & President | Sale 10b5-1 | −40,072 | $25.42 | $1.0M | 564,313 |
| 2024-03-11 | Brumm Joshua T CEO & President | Sale 10b5-1 | −9,928 | $26.10 | $259K | 554,385 |
| 2024-03-11 | Brumm Joshua T CEO & President | Sale 10b5-1 | −7,769 | $26.12 | $203K | 546,616 |
| 2024-03-11 | Brumm Joshua T CEO & President | Sale 10b5-1 | −8,618 | $25.93 | $223K | 537,998 |
| 2024-03-11 | Brumm Joshua T CEO & President | Option exercise · Stock option (right to buy) 10b5-1 | −50,000 | 83,269 | ||
| 2024-03-11 | Beskrovnaya Oxana Chief Scientific Officer | Sale 10b5-1 | −2,081 | $25.70 | $53K | 152,352 |
| 2024-03-08 | HIGH SUSANNA GATTI Chief Operating Officer | Sale 10b5-1 | −26,908 | $26.66 | $717K | 159,383 |
| 2024-03-08 | HIGH SUSANNA GATTI Chief Operating Officer | Sale 10b5-1 | −291 | $27.41 | $8K | 159,092 |
| 2024-03-08 | McNeill Jonathan Chief Business Officer | Option exercise 10b5-1 | +86,159 | $5.54 | $477K | 227,343 |
| 2024-03-08 | McNeill Jonathan Chief Business Officer | Option exercise 10b5-1 | +3,841 | $5.54 | $21K | 231,184 |
| 2024-03-08 | McNeill Jonathan Chief Business Officer | Sale 10b5-1 | −34,663 | $25.46 | $883K | 196,521 |
| 2024-03-08 | McNeill Jonathan Chief Business Officer | Sale 10b5-1 | −54,648 | $26.72 | $1.5M | 141,873 |
| 2024-03-08 | McNeill Jonathan Chief Business Officer | Sale 10b5-1 | −689 | $27.31 | $19K | 141,184 |
Page 20 of 29 · 561 trades